Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty.

What Happened? Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.1% in the afternoon session after the company reported second-quarter earnings that beat analyst ...

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined 5.8% over the past month. However, a closer look at its sound financials ...

Abbott Laboratories (NYSE:ABT) ranks among the best low volatility stocks to buy according to analysts. RBC Capital ...

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.

Shares of ABT stock opened at $131.00 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 52 week low of $99. ...

Conversely, if the dividend payment decreases, so will the yield. ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on Monday. Read More: ...